Stryker Corp. (SYK) reported first-quarter earnings that exceeded Wall Street expectations, driven by strong revenue and profit performance. The Kalamazoo, Michigan-based medical device manufacturer posted a quarterly profit of $592 million, translating to $1.54 per share on the reported basis.
On an adjusted basis, which excludes amortization and non-recurring costs, Stryker's earnings reached $2.14 per share, surpassing the average analyst estimate of $2.00 per share provided by Zacks Investment Research. The company also generated revenue of $4.78 billion for the quarter, beating the consensus forecast of $4.55 billion set by a group of ten analysts.
Looking ahead to the full year, Stryker has raised its earnings guidance, projecting annual earnings per share in the range of $10.05 to $10.25. This positive outlook follows a quarter where both top-line revenue and bottom-line profitability outperformed market predictions, signaling continued operational strength for the medical technology leader.
📈 Stryker Q1 profit hit $592 million, beating expectations.
💰 Adjusted EPS reached $2.14, above the $2.00 estimate.
💵 Revenue totaled $4.78 billion, surpassing the $4.55 forecast.
🚀 Full-year earnings guidance raised to $10.05–$10.25 per share.
📈 Stryker reported first-quarter profit of $592 million, beating Wall Street expectations.
💰 Adjusted earnings per share reached $2.14, exceeding the average analyst estimate of $2.00.
💵 Revenue totaled $4.78 billion for the quarter, surpassing the consensus forecast of $4.55 billion.
🚀 The company raised its full-year earnings guidance to a range of $10.05 to $10.25 per share.
📊 Results were based on data from Zacks Investment Research and reported by AP News.
Bullish Signals
Stryker Q1 profit hit $592M, beating expectations.
Adjusted EPS of $2.14 exceeded analyst estimates.
Revenue reached $4.78B, surpassing Street forecasts.
Full-year guidance raised to $10.05-$10.25 EPS.
Bullish Signals
Stryker's first-quarter profit of $592 million significantly exceeded market expectations, demonstrating strong financial execution.
Adjusted earnings per share of $2.14 beat the average analyst estimate of $2.00, indicating robust underlying business performance.
Revenue of $4.78 billion surpassed the Street forecast of $4.55 billion, highlighting effective top-line growth.
The company raised its full-year earnings guidance to $10.05-$10.25 per share, reflecting confidence in future profitability.
Stryker Corporation (NYSE:SYK) maintains a consensus 'Moderate Buy' rating from twenty-three brokerages, with sixteen analysts issuing buy ratings and six holding the stock. The average twelve-month price target stands at $392.52, though recent reports show mixed sentiment; Argus set a $370 target in late July, while Goldman Sachs reissued a neutral rating with a $361 target in May. Truist Financial lowered its objective to $330, and Weiss Ratings cut the stock's rating from 'hold (c+)' to 'hold (c)'.
Institutional ownership remains robust at 77.09%, with significant activity in the fourth quarter. Major funds including Vanguard Group, State Street Corp, Geode Capital Management, and Wellington Management Group increased their stakes, while Norges Bank initiated a new position valued at approximately $1.82 billion. These moves reflect continued institutional confidence despite recent analyst rating adjustments.
Financially, Stryker reported Q1 earnings of $2.60 per share, missing the consensus estimate of $2.98 by $0.38. Revenue came in at $6.02 billion, slightly below the expected $6.34 billion, representing a 2.6% year-over-year increase. The company posted a net margin of 13.20% and a return on equity of 23.42%. For fiscal 2026, management guidance ranges between $14.90 and $15.10 EPS, while analysts collectively predict $14.99 EPS.
The company declared a quarterly dividend of $0.88 per share, payable on July 31st to shareholders of record as of June 30th. This results in an annualized yield of 1.1% and a payout ratio of 40.74%. Stryker operates globally with a market cap of $126.77 billion, trading at a P/E ratio of 38.27. Its balance sheet shows a debt-to-equity ratio of 0.62, a current ratio of 2.11, and a quick ratio of 1.25.
📊 Consensus 'Moderate Buy' rating with $392.52 average price target.
📉 Q1 EPS missed estimates at $2.60 versus $2.98 consensus.
🏦 Institutional ownership stands at 77.09% with major funds increasing holdings.
💰 Quarterly dividend of $0.88 per share yields 1.1%.
🎯 FY 2026 EPS guidance set between $14.90 and $15.10.
📊 Stryker holds a consensus 'Moderate Buy' rating from 23 brokerages with an average 12-month price target of $392.52.
📉 Recent analyst actions include Goldman Sachs reissuing a neutral rating at $361 and Truist lowering its target to $330.
🏦 Institutional ownership is strong at 77.09%, with Vanguard, State Street, Geode, and Wellington increasing holdings in Q4.
📈 Norges Bank initiated a new position worth approximately $1.82 billion in the fourth quarter.
💰 The company declared a quarterly dividend of $0.88 per share with an annualized yield of 1.1%.
📉 Q1 earnings missed estimates with $2.60 EPS versus a consensus of $2.98 and revenue of $6.02 billion below expectations.
📈 Revenue grew 2.6% year-over-year to $6.02 billion, maintaining a net margin of 13.20%.
🎯 Management provided FY 2026 EPS guidance between $14.90 and $15.10 against analyst predictions of $14.99.
💵 The stock trades at a P/E ratio of 38.27 with a market capitalization of $126.77 billion.
🛡️ Financial health is supported by a debt-to-equity ratio of 0.62 and a current ratio of 2.11.
Bullish Signals
Moderate Buy rating from 23 brokerages.
Institutional investors increased stakes in Q4.
Norges Bank added $1.82 billion position.
$0.88 quarterly dividend with 1.1% yield.
Revenue grew 2.6% to $6.02 billion.
Debt-to-equity ratio of 0.62 and current ratio of 2.11.
Risk Factors
EPS of $2.60 missed consensus estimate of $2.98.
Revenue of $6.02B fell short of $6.34B expectations.
Goldman Sachs price target lowered to $361.
Weiss Ratings downgraded credit quality from c+ to c.
Bullish Signals
Stryker maintains a 'Moderate Buy' consensus rating from 23 brokerages, indicating broad institutional support.
Major institutional investors including Vanguard, State Street, Geode, and Wellington Management Group increased their stakes in the fourth quarter.
Norges Bank acquired a new position valued at approximately $1.82 billion, signaling significant foreign capital interest.
The company declared a quarterly dividend of $0.88 per share, providing an annualized yield of 1.1% to shareholders.
Revenue grew 2.6% year-over-year to $6.02 billion, demonstrating continued top-line growth despite missing earnings estimates.
Stryker maintains a healthy balance sheet with a debt-to-equity ratio of 0.62 and a current ratio of 2.11.
Risk Factors
Q1 earnings per share of $2.60 missed the consensus estimate of $2.98 by $0.38.
Revenue of $6.02 billion fell short of analyst expectations of $6.34 billion.
Goldman Sachs reissued a 'neutral' rating with a price target of $361, reflecting cautious sentiment.
Truist Financial lowered its price objective from $380 to $330 in a recent report.
Weiss Ratings cut the stock's rating from 'hold (c+)' to 'hold (c)', indicating a slight downgrade in credit quality.
Andra AP fonden significantly increased its position in Stryker Corporation (NYSE:SYK) by 30.2% in the first quarter, purchasing an additional 15,095 shares to hold a total of 65,055 shares valued at $21.4 million. This move aligns with several other institutional investors who recently established new stakes or added to their positions in the medical technology company during the third and fourth quarters.
Despite the institutional buying activity, Stryker reported mixed financial results for the quarter ended April 30th. The company posted earnings per share of $2.60, missing analyst consensus estimates of $2.98 by $0.38, while revenue reached $6.02 billion against an expected $6.34 billion. However, the company maintained a positive trajectory with revenue growing 2.6% year-over-year and setting full-year 2026 guidance between $14.90 and $15.10 per share.
Insider trading activity saw notable sales from executive VP Robert S. Fletcher and Director Ronda E. Stryker, with combined insider sales totaling over $100 million in the last three months. Analyst sentiment remains cautiously optimistic with a consensus 'Moderate Buy' rating and an average price target of $392.52, though recent downgrades from Wells Fargo and Barclays have lowered specific price targets to the high $300s.
📈 Andra AP fonden increased Stryker holdings by 30.2% to $21.4 million.
🏦 Multiple institutions established new stakes valued between $26,000 and $28,000.
💰 Institutional ownership stands at 77.09% while insiders own 4.60%.
📉 Q1 EPS of $2.60 missed estimates; revenue grew 2.6% to $6.02 billion.
💸 Insiders sold over $100 million in shares last three months.
📈 Andra AP fonden increased its Stryker holdings by 30.2% in Q1, adding 15,095 shares for a total value of $21.4 million.
🏦 Multiple other institutions including Godfrey Financial and Sankala Group established new stakes valued between $26,000 and $28,000 each.
💰 Institutional ownership stands at 77.09% while insiders own 4.60% of the company's stock.
📉 Stryker reported Q1 EPS of $2.60, missing analyst estimates of $2.98 by $0.38.
💵 Revenue for the quarter was $6.02 billion, slightly below the consensus estimate of $6.34 billion.
📈 Revenue grew 2.6% year-over-year to $6.02 billion despite the earnings miss.
🎯 The company set FY 2026 EPS guidance between $14.90 and $15.10.
💸 Insiders sold a total of 323,264 shares valued at over $100 million in the last three months.
📉 VP Robert S. Fletcher sold 4,544 shares under a pre-arranged Rule 10b5-1 trading plan.
📉 Director Ronda E. Stryker sold 310,000 shares worth $96.8 million in a single transaction.
💰 The company declared a quarterly dividend of $0.88 per share payable on July 31st.
📉 Wells Fargo reduced its price target from $456 to $418 while maintaining an 'overweight' rating.
📉 Barclays lowered its price objective from $469 to $394 but kept an 'overweight' rating.
📈 BMO Capital Markets initiated coverage with an 'outperform' rating and a $369 price target.
🏆 The stock holds a consensus 'Moderate Buy' rating with an average analyst price target of $392.52.
Bullish Signals
Stake increased 30.2% by Andra AP fonden.
Revenue grew 2.6% YoY to $6.02 billion.
Full-year 2026 EPS guidance set at $14.90-$15.10.
Dividend yield of 1.1% with 40.74% payout ratio.
Institutional ownership stands high at 77.09%.
Risk Factors
Missed earnings by $0.38; reported $2.60 EPS vs $2.98 consensus.
Revenue fell short at $6.02B vs $6.34B expectations.
Wells Fargo cut price target from $456 to $418.
Barclays lowered objective from $469 to $394.
Insiders sold over $100 million in last three months.
Bullish Signals
Andra AP fonden increased its stake by 30.2% in Q1, signaling strong institutional confidence in the company's long-term prospects.
Several other large investors including Godfrey Financial, Sankala Group, and DJE Kapital established new positions or added to existing stakes.
Revenue grew 2.6% year-over-year to $6.02 billion, demonstrating continued top-line growth despite a quarterly earnings miss.
The company has set robust full-year 2026 guidance of $14.90-$15.10 EPS, with analysts anticipating $14.99 EPS for the current year.
Stryker maintains a healthy dividend yield of 1.1% with a payout ratio of 40.74%, providing income to shareholders.
Institutional ownership remains high at 77.09%, indicating broad market interest and stability in the stock.
Risk Factors
Stryker missed quarterly earnings estimates by $0.38 per share, reporting $2.60 EPS against a consensus of $2.98.
Revenue of $6.02 billion fell short of analyst expectations of $6.34 billion for the quarter.
Wells Fargo reduced its price target from $456 to $418, citing concerns that may impact valuation multiples.
Barclays lowered its price objective from $469 to $394, reflecting a more cautious near-term outlook.
Significant insider selling occurred in the last three months, with insiders offloading over $100 million worth of shares.
AIA Group Ltd reduced its stake in Stryker Corporation (NYSE:SYK) by 8.4% in the first quarter, selling 1,624 shares to hold a remaining position of 17,738 shares valued at $5.829 million. While AIA decreased its holdings, several other institutional investors including Sankala Group LLC, Godfrey Financial Associates Inc., and DJE Kapital AG established new positions in the medical technology company during the third or fourth quarter, with individual stakes ranging from approximately $26,000 to $28,000. Institutional ownership of SYK remains high at 77.09%.
Analyst sentiment for Stryker is mixed but generally positive, with a consensus target price of $392.52 and an average rating of 'Moderate Buy' based on data from MarketBeat.com. Wells Fargo & Company lowered its price objective to $418.00 while maintaining an 'overweight' rating, whereas BMO Capital Markets initiated coverage with an 'outperform' rating and a $369.00 target. The stock currently trades around $319.78, trading below its 200-day moving average of $336.71 but above its 50-day moving average of $312.69.
Financially, Stryker reported Q1 earnings of $2.60 EPS, missing the consensus estimate of $2.98 by $0.38, with revenue of $6.02 billion falling short of the $6.34 billion forecast. Despite the miss, the company posted a 2.6% year-over-year revenue increase and maintains strong balance sheet metrics including a P/E ratio of 37.01 and a debt-to-equity ratio of 0.62. The company has set full-year 2026 EPS guidance between $14.90 and $15.10, with analysts expecting $14.99.
Corporate insiders have been active sellers recently, with Vice Presidents Robert S. Fletcher and M Kathryn Fink reducing their personal holdings by over 28% each in May transactions totaling nearly $2.9 million combined. In total, corporate insiders sold approximately 323,264 shares valued at over $100 million in the last three months. The company also declared a quarterly dividend of $0.88 per share payable on July 31st to shareholders of record on June 30th, representing an annualized yield of 1.1%.
📉 AIA Group sold shares, reducing stake to $5.829 million value.
📊 Institutional investors own 77.09% of outstanding Stryker shares.
💰 Consensus analyst price target is $392.52 with Moderate Buy rating.
📉 Q1 EPS missed estimates at $2.60 versus $2.98 consensus.
💵 Revenue grew 2.6% to $6.02 billion, missing expectations.
📉 AIA Group Ltd sold 1,624 shares of Stryker in Q1, reducing its stake by 8.4% to a remaining value of $5.829 million.
🆕 Multiple hedge funds including Sankala Group LLC and DJE Kapital AG established new positions in SYK valued between $26,000 and $28,000.
📊 Institutional investors own 77.09% of Stryker Corporation's outstanding shares.
📉 Wells Fargo cut its price target to $418.00 while maintaining an 'overweight' rating on the stock.
🎯 BMO Capital Markets initiated coverage with an 'outperform' rating and a $369.00 price target.
💰 The consensus analyst price target for SYK is $392.52 with an average rating of 'Moderate Buy'.
📉 Stryker reported Q1 EPS of $2.60, missing the consensus estimate of $2.98 by $0.38.
💵 Revenue for the quarter was $6.02 billion, representing a 2.6% increase compared to the prior year.
📉 The stock missed revenue expectations of $6.34 billion during the first quarter.
📈 Stryker set full-year 2026 EPS guidance between $14.90 and $15.10.
💸 Corporate insiders sold approximately 323,264 shares valued at over $100 million in the last three months.
📉 VP Robert S. Fletcher sold 4,544 shares for $1.39 million under a pre-arranged trading plan.
💰 The company declared a quarterly dividend of $0.88 per share with an ex-dividend date of June 30th.
📉 VP M Kathryn Fink sold 5,220 shares for $1.48 million in early May.
📊 Stryker trades at a P/E ratio of 37.01 with a market capitalization of $122.59 billion.
📉 The stock price is currently below its 200-day moving average of $336.71.
🏥 Stryker operates in orthopedics, surgical equipment, neurotechnology, and patient-handling equipment sectors.
📈 The company maintains a quick ratio of 1.25 and a current ratio of 2.11.
📉 Net margin for the quarter was 13.20% with a return on equity of 23.42%.
📅 Analysts anticipate Stryker will post $14.99 EPS for the current fiscal year.
Bullish Signals
Multiple institutional investors established new positions in Q3/Q4.
BMO Capital Markets initiated coverage with 'outperform' rating and $369 target.
Revenue increased 2.6% YoY to $6.02 billion despite missing estimates.
Strong balance sheet: quick ratio 1.25, current ratio 2.11, debt-to-equity 0.62.
Full-year 2026 EPS guidance set between $14.90 and $15.10.
Quarterly dividend of $0.88 per share with 1.1% annualized yield.
Risk Factors
EPS missed by $0.38 at $2.60 vs $2.98 consensus.
Revenue fell short of $6.34 billion forecast at $6.02B.
Insiders sold over $100 million in shares recently.
Wells Fargo lowered price target to $418 from $456.
Bullish Signals
Multiple institutional investors including Sankala Group LLC, Godfrey Financial Associates Inc., and DJE Kapital AG established new positions in Stryker during Q3 or Q4.
BMO Capital Markets initiated coverage with an 'outperform' rating and a $369.00 price target.
Stryker reported a 2.6% year-over-year revenue increase to $6.02 billion despite missing consensus estimates.
The company maintains a strong balance sheet with a quick ratio of 1.25, current ratio of 2.11, and debt-to-equity ratio of 0.62.
Stryker has set full-year 2026 EPS guidance between $14.90 and $15.10, with analysts expecting $14.99.
The company declared a quarterly dividend of $0.88 per share representing an annualized yield of 1.1%.
Risk Factors
Stryker reported Q1 EPS of $2.60, missing the consensus estimate of $2.98 by $0.38.
Revenue for the quarter was $6.02 billion, falling short of the $6.34 billion consensus forecast.
Corporate insiders sold approximately 323,264 shares valued at over $100 million in the last three months.
Vice Presidents Robert S. Fletcher and M Kathryn Fink reduced their personal holdings by over 28% each in May transactions.
The stock price is currently trading below its 200-day moving average of $336.71.
Wells Fargo & Company lowered its price objective from $456.00 to $418.00.
Atlas Wealth LLC established a new position in Stryker Corporation (NYSE:SYK) during the first quarter, purchasing 36,760 shares valued at approximately $12.08 million. This investment represents 1.5% of Atlas Wealth's portfolio and ranks as its 19th largest holding. Several other institutional investors also adjusted their stakes in the medical technology company during the fourth quarter, with Czech National Bank increasing its position by 3.9%, Daymark Wealth Partners growing theirs by 436.0%, Varma Mutual Pension Insurance raising its stake by 10.5%, and Wealthcare Advisory Partners expanding its holding by 265.2%. CIBC Bancorp USA also acquired a new position worth $17.5 million in the third quarter.
Institutional ownership of Stryker stands at 77.09% as of the latest filings. However, insider selling activity has been notable recently. Director Ronda E. Stryker sold 310,000 shares on May 26th for a total value of $96.8 million, reducing her personal stake by 13.87%. Additionally, Vice President M Kathryn Fink sold 5,220 shares on May 11th for $1.48 million, decreasing her position by 28.44%. Over the last three months, insiders have collectively sold 323,264 shares valued at approximately $100.7 million, leaving 4.60% of the stock currently owned by insiders.
Financially, Stryker reported quarterly earnings on April 30th that missed analyst expectations. The company posted earnings per share (EPS) of $2.60 against a consensus estimate of $2.98, and revenue reached $6.02 billion compared to the expected $6.34 billion. Despite the miss, the firm achieved a return on equity of 23.42% and a net margin of 13.20%, with revenue growing 2.6% year-over-year. The company has set full-year 2026 guidance between $14.90 and $15.10 per share, while analysts currently expect EPS of $14.99 for the current year.
Stryker recently announced a quarterly dividend to be paid on July 31st to shareholders of record as of June 30th. The dividend amount is $0.88 per share, representing an annualized yield of 1.1% and a payout ratio of 40.74%. Analyst sentiment remains mixed with varying price targets; Deutsche Bank set a target of $315, Needham lowered its objective to $418 with a buy rating, Leerink Partners adjusted its target to $407, BMO Capital Markets initiated coverage with an outperform rating and $369 target, and Wells Fargo reduced its target to $418. The aggregate average price target from MarketBeat is $392.52 based on ratings ranging from Strong Buy to Hold.
🏦 Institutional investors own 77.09% of Stryker's outstanding stock.
💸 Insiders sold 323,264 shares worth $100.7 million recently.
📉 Q1 EPS missed estimates at $2.60 versus $2.98 consensus.
💰 Revenue reached $6.02 billion, up 2.6% year-over-year.
🎯 Full-year 2026 guidance set between $14.90 and $15.10.
📈 Atlas Wealth LLC purchased a new position of 36,760 shares valued at $12.08 million in Stryker during the first quarter.
📉 Czech National Bank increased its stake by 3.9% to own 90,755 shares worth $31.9 million in the fourth quarter.
🚀 Daymark Wealth Partners expanded its position by 436.0%, acquiring an additional 37,307 shares valued at $16.1 million.
📈 Varma Mutual Pension Insurance raised its stake by 10.5% to own 53,610 shares worth $18.8 million.
🚀 Wealthcare Advisory Partners grew its position by 265.2%, purchasing an additional 6,774 shares valued at $3.3 million.
📉 CIBC Bancorp USA acquired a new position in the third quarter worth $17.5 million.
🏦 Institutional investors collectively own 77.09% of Stryker Corporation's outstanding stock.
💸 Director Ronda E. Stryker sold 310,000 shares for $96.8 million on May 26th, reducing her stake by 13.87%.
💸 VP M Kathryn Fink sold 5,220 shares for $1.48 million on May 11th, decreasing her position by 28.44%.
📉 Insiders have sold a total of 323,264 shares valued at $100.7 million over the last three months.
📉 Stryker reported Q1 EPS of $2.60, missing the consensus estimate of $2.98 by $0.38.
💰 The company generated revenue of $6.02 billion, which was 2.6% higher than the prior year period.
📊 Stryker achieved a return on equity of 23.42% and a net margin of 13.20% for the quarter.
🎯 The firm set full-year 2026 guidance between $14.90 and $15.10 per share in earnings.
💵 Stryker announced a quarterly dividend of $0.88 per share to be paid on July 31st.
📈 The dividend represents an annualized yield of 1.1% with a payout ratio of 40.74%.
📉 Deutsche Bank set a price target of $315.00 in a research report issued on May 1st.
📉 Needham & Company lowered its price objective to $418.00 while maintaining a buy rating.
📉 Leerink Partners reduced its price target to $407.00 and set an outperform rating.
📈 BMO Capital Markets initiated coverage with an outperform rating and a $369.00 price target.
📉 Wells Fargo & Company reduced its target price to $418.00 with an overweight rating.
📊 MarketBeat reports an average analyst price target of $392.52 with a Moderate Buy consensus.
Bullish Signals
Atlas Wealth bought $12.08M shares as 19th largest holding.
Czech National Bank added 3,366 shares, up 3.9%.
Daymark Wealth expanded position by 436.0%, adding 37,307 shares.
Wealthcare Advisory Partners grew position by 265.2%, adding 6,774 shares.
CIBC Bancorp USA acquired new $17.5M position in Q3.
Stryker achieved 23.42% ROE and 13.20% net margin.
Revenue grew 2.6% YoY to $6.02 billion.
Full-year 2026 EPS guidance set between $14.90 and $15.10.
Quarterly dividend of $0.88 with 1.1% annualized yield.
Risk Factors
EPS missed by $0.38 at $2.60 vs $2.98 estimate.
Revenue fell short at $6.02B vs $6.34B expectation.
Directors sold 310k shares worth $96.8 million.
Insiders sold 323k shares valued at $100.7 million.
Average analyst target of $392.52 is lower than highs.
Bullish Signals
Atlas Wealth LLC initiated a new position in Stryker, purchasing shares valued at $12.08 million to make it its 19th largest holding.
Czech National Bank increased its stake by 3.9% during the fourth quarter, adding 3,366 shares to its portfolio.
Daymark Wealth Partners significantly expanded its position by 436.0%, acquiring an additional 37,307 shares in the fourth quarter.
Varma Mutual Pension Insurance raised its stake by 10.5% during the fourth quarter, purchasing an additional 5,100 shares.
Wealthcare Advisory Partners grew its position by 265.2%, acquiring an additional 6,774 shares in the fourth quarter.
CIBC Bancorp USA acquired a new position in Stryker during the third quarter worth $17.5 million.
Stryker achieved a return on equity of 23.42% and a net margin of 13.20% despite missing earnings estimates.
The company reported revenue growth of 2.6% year-over-year, reaching $6.02 billion for the quarter.
Stryker has set full-year 2026 guidance between $14.90 and $15.10 EPS, indicating management confidence in future performance.
The company announced a quarterly dividend of $0.88 per share with an annualized yield of 1.1%.
Risk Factors
Stryker reported earnings per share of $2.60, which missed the consensus estimate of $2.98 by $0.38.
The company's revenue of $6.02 billion fell short of analyst expectations of $6.34 billion for the quarter.
Director Ronda E. Stryker sold 310,000 shares worth $96.8 million, representing a 13.87% decrease in her personal stake.
Vice President M Kathryn Fink sold 5,220 shares worth $1.48 million, reducing her position by 28.44%.
Insiders have collectively sold 323,264 shares valued at $100.7 million over the last three months.
Deutsche Bank set a price target of $315.00, which is below the current market price implied by other targets.
Needham & Company decreased its price objective from $454.00 to $418.00 while maintaining a buy rating.
Leerink Partners lowered their price objective from $410.00 to $407.00 in a recent report.
Wells Fargo & Company reduced its target price on Stryker from $456.00 to $418.00.
The average analyst price target of $392.52 is lower than the previous high targets set by Needham and Wells Fargo.
This article evaluates Stryker Corporation (NYSE: SYK) as a top medical device stock, ranking it ninth on a list of elite hedge fund picks. The analysis highlights the broader medical device market's projected growth to $955.49 billion by 2030, driven by an aging global population and technological advancements like AI and robotics.
Stryker operates in Neurotechnology, Medical and Surgical, and Orthopedics segments, holding approximately 13,000 patents. The company demonstrated resilience with annual sales never dropping more than 6% historically and a streak of 31 consecutive years of dividend payments. In fiscal Q4 2024, the firm reported record installations for its Mako robotic-assisted surgery systems.
Financial performance metrics show strong momentum, with 10% year-over-year organic sales growth in both fiscal Q4 2024 and full-year 2024. Adjusted earnings per share increased by 16% year-over-year in the fourth quarter of 2024. The company also completed seven acquisitions in 2024, including Inari Medical, to expand its presence in the peripheral vascular market.
Parnassus Core Equity Fund praises Stryker as a best-in-class provider with dominant orthopedics leadership and optimism regarding upcoming product launches. However, the article concludes by suggesting that AI stocks may offer higher returns in shorter timeframes, though it maintains SYK's strong position within the medical device sector.
📈 Ranked 9th among top medical device stocks by elite hedge funds in Q3 2024.
🌍 Global market projected to hit $955.49 billion by 2030 at 6.99% CAGR.
🦴 Holds 13,000 patents across neurotechnology, surgical, and orthopedics segments.
💰 Paid dividends for 31 years with sales never dropping over 6% since 1984.
📊 Reported 10% organic sales growth and 16% EPS increase in fiscal Q4 2024.
📈 Stryker Corporation (NYSE: SYK) is ranked ninth on a list of top medical device stocks selected by elite hedge funds based on Q3 2024 sentiment data.
🌍 The global medical devices market is projected to reach $955.49 billion by 2030, growing at a compound annual rate of 6.99% driven by demographic shifts.
🦴 Stryker operates across Neurotechnology, Medical and Surgical, and Orthopedics segments, holding approximately 13,000 global patents to protect its product portfolio.
💰 The company has maintained a streak of paying and raising dividends for 31 consecutive years with annual sales never dropping more than 6% since 1984.
🤖 Record installations were achieved for the Mako robotic-assisted surgery systems in the U.S. and globally during fiscal Q4 2024.
📊 Stryker reported 10% year-over-year organic sales growth for both fiscal Q4 2024 and the full-year 2024.
💹 Adjusted earnings per share increased by 16% year-over-year in fiscal Q4 2024, reflecting strong profitability.
🤝 The company completed seven acquisitions in 2024, including Inari Medical, to strengthen its market position in the peripheral vascular sector.
⭐ Parnassus Core Equity Fund views Stryker as a best-in-class provider with significant revenue and market share growth compared to competitors.
🚀 Upcoming product launches and the expansion of the Mako robotic-assisted surgery arm are cited as key drivers for future optimism.
Bullish Signals
10% organic sales growth in Q4 2024 and full-year 2024.
16% adjusted EPS increase in fiscal Q4 2024.
Seven acquisitions in 2024, including Inari Medical purchase.
Approximately 13,000 global patents provide competitive moat.
31 consecutive years of paying and raising dividends.
Bullish Signals
Stryker reported 10% year-over-year organic sales growth in both fiscal Q4 2024 and full-year 2024, indicating robust demand for its products.
The company achieved a 16% year-over-year increase in adjusted EPS during fiscal Q4 2024, demonstrating strong earnings power.
Stryker completed seven acquisitions in 2024, including the purchase of Inari Medical, to expand its footprint in high-growth peripheral vascular markets.
The firm holds approximately 13,000 global patents, providing a durable competitive moat against replication by competitors.
Stryker has maintained a consistent track record of paying and raising dividends for 31 consecutive years, signaling financial stability.
Record installations of the Mako robotic-assisted surgery systems occurred in fiscal Q4 2024, highlighting strong adoption of its innovative technology.
Parnassus Core Equity Fund identifies Stryker as a leader in orthopedics with a broad product offering driving significant revenue growth.
Bank of New York Mellon Corp reduced its stake in Stryker Corporation (NYSE:SYK) by 8.3% in the first quarter, selling 359,418 shares to hold a remaining position of 3,952,401 shares valued at approximately $1.3 billion. While BNY Mellon decreased its holding, several other institutional investors and hedge funds initiated new positions in the fourth or third quarters, with stakes ranging from roughly $26,000 to $28,000 each, contributing to a total institutional ownership of 77.09%.
Analyst sentiment remains mixed but generally positive regarding Stryker's long-term prospects. BTIG Research set a $371 target price, while Canaccord Genuity lowered its target from $435 to $400 but maintained a 'buy' rating. Goldman Sachs restated a neutral rating with a $361 target, and BMO Capital Markets initiated coverage with an 'outperform' rating and $369 target. The consensus average target price stands at $392.52 based on data from MarketBeat.com.
Financially, Stryker reported Q1 earnings of $2.60 per share, missing the consensus estimate of $2.98 by $0.38, with revenue of $6.02 billion falling short of the $6.34 billion expected. Despite the miss, revenue grew 2.6% year-over-year to a net margin of 13.20%. The company has provided FY 2026 guidance for EPS between $14.90 and $15.10, while insiders have sold significant shares recently, including Director Ronda E. Stryker selling over $96 million worth of stock.
The stock currently trades at a market cap of $121.32 billion with a price-to-earnings ratio of 36.63 and a beta of 0.77. Shares opened at $316.46, trading above its 50-day moving average but below its 200-day average. Stryker also declared a quarterly dividend of $0.88 per share, payable on July 31st to shareholders of record on June 30th, representing an annualized yield of 1.1% and a payout ratio of 40.74%.
📉 Bank of New York Mellon sold 359,418 shares while keeping a $1.3 billion stake.
💰 Institutional ownership stands at 77.09% with multiple new positions in Q3 and Q4.
📊 Goldman Sachs set a $361 target; BTIG set a $371 target price.
📉 Q1 EPS of $2.60 missed estimates, though revenue rose 2.6% to $6.02 billion.
💸 Quarterly dividend declared at $0.88 per share with an ex-date of June 30th.
📉 Bank of New York Mellon Corp reduced its Stryker stake by 8.3% in Q1, selling 359,418 shares while retaining a $1.3 billion position.
📈 Multiple hedge funds and institutional investors initiated new positions in SYK during the third and fourth quarters.
💰 Institutional ownership of Stryker Corporation stands at 77.09% as of the latest SEC filings.
🎯 BTIG Research set a $371 target price, while Canaccord Genuity lowered its target to $400 but maintained a 'buy' rating.
📊 Goldman Sachs restated a neutral rating with a $361 target, and BMO Capital Markets initiated coverage with an 'outperform' rating.
📉 Stryker reported Q1 EPS of $2.60, missing the consensus estimate of $2.98 by $0.38.
💵 Revenue for the quarter reached $6.02 billion, representing a 2.6% increase compared to the same period last year.
📉 The company missed revenue estimates of $6.34 billion and reported a net margin of 13.20%.
🔮 Stryker provided FY 2026 guidance for EPS between $14.90 and $15.10, slightly below analyst predictions of $14.98.
💸 The company declared a quarterly dividend of $0.88 per share with an ex-dividend date of June 30th.
📉 Director Ronda E. Stryker sold 310,000 shares worth approximately $96.8 million in a recent transaction.
📉 VP Robert S. Fletcher sold 4,544 shares worth approximately $1.4 million under a pre-arranged trading plan.
📉 Insiders have collectively sold 323,264 shares worth over $100.6 million over the last 90 days.
📈 The stock trades at a market cap of $121.32 billion with a PEG ratio of 1.99 and a beta of 0.77.
📉 Shares opened at $316.46, trading above the 50-day moving average but below the 200-day moving average.
Bullish Signals
Multiple institutional investors initiated new positions in Q3/Q4.
Stryker achieved $6.02B revenue, up 2.6% year-over-year.
Net margin is 13.20% and ROE is 23.42%.
Analyst target price of $392.52 exceeds current trading price.
Strong balance sheet with current ratio of 2.11.
Risk Factors
Missed Q1 earnings by $0.38 per share.
Revenue fell short of $6.34 billion estimate.
Canaccord Genuity lowered price target to $400.
Goldman Sachs restated rating with $361 target.
Insiders sold over $100 million in 90 days.
Bullish Signals
Multiple institutional investors and hedge funds initiated new positions in Stryker during Q3 and Q4, indicating continued interest from capital markets.
Stryker achieved a 2.6% year-over-year revenue increase to $6.02 billion despite missing analyst expectations.
The company maintains a healthy net margin of 13.20% and a return on equity of 23.42%.
Analyst consensus remains 'Moderate Buy' with an average target price of $392.52, which is above the current trading price.
BMO Capital Markets initiated coverage with an 'outperform' rating and a $369 target price.
Stryker has a strong balance sheet with a current ratio of 2.11 and a debt-to-equity ratio of 0.62.
Risk Factors
Stryker missed Q1 earnings estimates by $0.38 per share, reporting $2.60 EPS against a consensus of $2.98.
Revenue of $6.02 billion fell short of the $6.34 billion analyst estimate for the quarter.
Canaccord Genuity reduced its price target from $435 to $400, reflecting some near-term concerns.
Goldman Sachs restated its rating to 'neutral' with a lower $361 price target.
Significant insider selling occurred recently, with Director Ronda E. Stryker and VP Robert S. Fletcher reducing their holdings by 13.87% and 30.04% respectively.
Insiders have sold over $100 million worth of stock in the last 90 days, totaling 4.60% of outstanding shares.
AMG National Trust Bank increased its stake in Stryker Corporation (NYSE:SYK) by 18.9% during the first quarter, purchasing an additional 2,927 shares to hold a total of 18,422 shares valued at $6.053 million according to SEC filings. Several other institutional investors including VanderPol Investments, KCM Investment Advisors, and Rossby Financial also adjusted their positions in the fourth quarter, with holdings ranging from roughly 451 to 2,084 shares each.
Stryker Corporation reported a market capitalization of $127.35 billion with a debt-to-equity ratio of 0.62 and a current ratio of 2.11. The stock opened at $332.20 on Tuesday, trading between a one-year low of $281.00 and a high of $404.87. Analyst consensus targets the stock at $392.52 with an average rating of Moderate Buy, though recent reports from Wall Street Zen, Truist Financial, and JPMorgan Chase have lowered price targets or maintained neutral/hold ratings.
The company declared a quarterly dividend of $0.88 per share payable on July 31st to shareholders of record as of June 30th, resulting in an annualized yield of 1.1% with a payout ratio of 40.74%. However, insider selling activity was significant in the last 90 days, with Vice Presidents Robert S. Fletcher and M Kathryn Fink reducing their holdings by over 30% and 95% respectively, totaling $100.66 million in insider sales.
🏦 AMG National Trust Bank increased SYK stake by 18.9% to $6.053 million.
📊 Stryker trades at $127.35B market cap with P/E of 38.45 and beta 0.77.
💰 Quarterly dividend is $0.88 per share yielding 1.1% annually.
📉 Insiders sold $100.66 million in shares over the last 90 days.
📉 Analysts lowered targets with mixed sentiment and Moderate Buy consensus rating.
🏦 AMG National Trust Bank boosted its SYK stake by 18.9% to 18,422 shares worth $6.053 million in Q1.
📊 Stryker trades at a market cap of $127.35 billion with a P/E ratio of 38.45 and a beta of 0.77.
💰 The company declared a quarterly dividend of $0.88 per share with an annualized yield of 1.1%.
📉 Insider selling was heavy in the last 90 days, totaling $100.66 million as executives reduced positions significantly.
📉 Analyst sentiment is mixed with recent downgrades from Wall Street Zen and JPMorgan Chase lowering price targets.
🏥 Stryker operates globally in orthopedics, surgical equipment, neurotechnology, and patient-handling solutions.
📈 The stock currently has a consensus target price of $392.52 with an average rating of Moderate Buy.
Bullish Signals
AMG National Trust Bank increased position by 18.9% in Q1.
Strong balance sheet with debt-to-equity ratio of 0.62 and current ratio of 2.11.
Stryker offers quarterly dividend with 1.1% yield.
Risk Factors
Insiders sold $100.66 million in the last 90 days.
Raymond James upgraded Stryker (NYSE: SYK) to an Outperform rating with a $418 price target, citing the company as a high-quality large-cap MedTech stock. The firm notes that while Stryker has achieved double-digit sales growth for five consecutive years, its valuation multiple appears compressed, suggesting a potential buying opportunity.
Following the upgrade, Stryker shares rose more than 3% in early trading. This positive market reaction aligns with investor sentiment regarding the company's fundamental performance versus its current stock price multiple.
The article also briefly covers other market movers including AngioDynamics, which saw its stock drop 13% despite a revenue beat due to negative full-year guidance, and Ford Motor, which reported record annual sales but faced challenges in EV segments and Q4 pickup sales.
📈 Raymond James upgrades Stryker to Outperform with $418 target.
💰 Stryker shows high quality and compressed valuation after growth.
📊 Stryker shares gain over 3% following analyst upgrade.
🚗 Ford reports record annual vehicle sales of 2.2 million units.
⚠️ AngioDynamics stock falls 13% on full-year loss forecast.
📈 Raymond James upgraded Stryker (SYK) to Outperform with a $418 price target.
💰 Analysts view Stryker as a high-quality stock with compressed valuation multiples after five years of 10%+ sales growth.
📊 Stryker shares gained over 3% in early trading following the upgrade announcement.
🔍 The upgrade suggests investors see value in buying SYK at current levels despite recent price compression.
🚗 Ford Motor reported record annual vehicle sales of 2.2 million units for 2025.
⚠️ AngioDynamics (ANGO) stock fell 13% after issuing a loss forecast for the full year.
Bullish Signals
Raymond James upgraded Stryker with a $418 price target.
Stryker grew sales 10%+ for five consecutive years.
Stock price jumped over 3% after the upgrade.
Bullish Signals
Raymond James upgraded Stryker to Outperform with a $418 price target, signaling strong institutional confidence in the company's quality and growth trajectory.
Stryker has demonstrated consistent operational excellence by growing sales 10% or better for five consecutive years.
The stock price increased more than 3% immediately following the upgrade, reflecting positive market reception to the analyst action.
Stryker Corporation (NYSE:SYK) saw significant changes in institutional ownership during the first quarter, led by Azzad Asset Management Inc., which increased its stake by 1,006.4% to hold 6,406 shares valued at $2.1 million. Several other firms, including Godfrey Financial Associates and Sankala Group, established new positions ranging from $26,000 to $28,000 each, while institutional investors collectively own 77.09% of the company's stock.
Corporate insiders executed substantial sales in May, with VP M Kathryn Fink selling 5,220 shares for approximately $1.48 million and Director Ronda E. Stryker offloading 310,000 shares worth roughly $96.8 million. These transactions resulted in a combined insider sale of over 323,000 shares valued at more than $100 million during the last quarter, reducing corporate insider ownership to 4.60%.
Financially, Stryker reported Q1 earnings of $2.60 per share, missing analyst estimates of $2.98, alongside revenue of $6.02 billion that fell short of the $6.34 billion consensus. Despite the miss, the company maintained a 13.20% net margin and 23.42% return on equity, with revenue growing 2.6% year-over-year. The stock trades at a market cap of $126.46 billion with a P/E ratio of 38.18.
Looking ahead, Stryker has provided full-year 2026 guidance for EPS between $14.90 and $15.10, slightly below the analyst expectation of $14.98. The company also declared a quarterly dividend of $0.88 per share, payable on July 31st to shareholders of record by June 30th, representing an annualized yield of 1.1% and a payout ratio of 40.74%.
Debt-to-equity ratio of 0.62; current ratio of 2.11.
$0.88 quarterly dividend yielding 1.1%.
Risk Factors
EPS missed by $0.38 at $2.60 vs $2.98 estimate.
Revenue fell short at $6.02B vs $6.34B estimate.
Insiders sold 323,264 shares worth $100.6 million.
Full-year 2026 EPS guidance of $14.90-$15.10 below expectations.
Bullish Signals
Institutional ownership remains strong at 77.09%, with Azzad Asset Management significantly increasing its position by over 1,000%.
Multiple new institutional investors entered positions in Q3 and Q4, including Godfrey Financial Associates, Sankala Group, United Financial Planning Group, Atlas Capital Advisors, and DJE Kapital AG.
The company reported year-over-year revenue growth of 2.6%, demonstrating continued top-line expansion despite missing earnings estimates.
Stryker maintains a healthy balance sheet with a debt-to-equity ratio of 0.62, a quick ratio of 1.25, and a current ratio of 2.11.
The company declared a quarterly dividend of $0.88 per share, providing a 1.1% yield to shareholders.
Risk Factors
Q1 earnings per share of $2.60 missed the consensus estimate of $2.98 by $0.38.
Revenue of $6.02 billion fell short of analyst estimates of $6.34 billion.
Significant insider selling occurred in May, with VP M Kathryn Fink and Director Ronda E. Stryker reducing their holdings by 28.44% and 13.87% respectively.
Corporate insiders sold a total of 323,264 shares worth $100.6 million in the last quarter.
Full-year 2026 EPS guidance of $14.90-$15.10 is below analyst expectations of $14.98.
Stryker Corporation (SYK) is a global medical technology leader specializing in orthopedic implants, surgical equipment, and hospital infrastructure. Its diverse portfolio includes hip and knee replacement systems, trauma devices, spine products, endoscopic instruments, patient mobility solutions, and robotic-assisted surgery platforms like Mako. The company operates in markets driven by demographic aging, increasing procedure volumes, and hospital investment cycles.
Stryker combines established implant franchises with recurring demand for consumables and equipment, providing exposure to both elective procedures and broader hospital capital spending. While the United States remains its primary market, significant international sales contribute substantially to total revenue. Investors view Stryker as a large-cap healthcare play with deep surgeon relationships and long-term growth tied to musculoskeletal care and hospital modernization.
Recent analyst sentiment is strongly positive, with 82% of analysts rating the stock a Buy and no recent rating changes recorded. Technical indicators show the price trading above the 50-day moving average with supportive MACD momentum and bullish RSI, though the 200-day moving average remains lower. However, insider selling presents a notable negative factor, with net sales of approximately $37.5 million over the last 90 days and no meaningful purchases.
🏥 Global leader in orthopedic implants, surgical equipment, and robotic platforms.
💰 High-margin implant franchises paired with recurring consumable revenue streams.
📈 Strong analyst sentiment: 82% Buy ratings with no recent downgrades.
🔬 Capitalizes on aging population and minimally invasive procedure trends.
💸 Insider selling offset by bullish technical indicators and international diversification.
🏥 Stryker Corporation operates globally in orthopedic implants, surgical equipment, and hospital infrastructure including robotic surgery platforms.
💰 The business model combines high-margin implant franchises with recurring revenue from consumables and capital equipment sales.
📈 Analyst sentiment is strongly positive with 82% of analysts rating Stryker as a Buy and no recent downgrades.
📊 Technical indicators are supportive in the near term, with price above the 50-day moving average and bullish MACD momentum.
💸 Insider selling is a primary negative factor, with net sales of approximately $37.5 million over the last 90 days.
🌍 Significant international revenue diversifies exposure beyond the United States market.
🔬 The company benefits from long-term secular trends including population aging and demand for minimally invasive procedures.
Bullish Signals
82% of analysts rate Stryker as a Buy.
Stock trades above 50-day moving average with bullish MACD.
Benefits from secular tailwinds like population aging.
Risk Factors
Insider sold $37.5M of stock in last 90 days.
200-day moving average indicates medium-term bearish pressure.
Bullish Signals
Analyst sentiment remains strongly positive with 82% of analysts rating Stryker as a Buy, indicating strong institutional confidence in the stock.
Technical signals are supportive in the near term, with the stock price trading above the 50-day moving average and showing bullish MACD momentum.
The company benefits from durable secular tailwinds including population aging, increasing procedure volumes, and hospital investment cycles.
Risk Factors
Insider selling is the main negative factor, with net sales of approximately $37.5 million in Stryker stock over the last 90 days.
Technical analysis shows the 200-day moving average still points lower, suggesting potential medium-term resistance or bearish pressure.
AdvisorShares Investments LLC reduced its position in Stryker Corporation (NYSE:SYK) by 8.8% during the first quarter, selling 1,794 shares to hold a remaining stake of 18,632 shares valued at $6.12 million. This reduction makes Stryker the firm's 25th largest holding, representing approximately 1.1% of its total portfolio as reported in recent SEC filings.
Conversely, several other institutional investors and hedge funds increased their exposure to the medical technology company during the second and fourth quarters. Brighton Jones LLC boosted its position by 15.4%, while Marshall Wace LLP significantly increased its stake by 107.9% to own 5,700 shares valued at $2.255 million. Other new positions were acquired by Schnieders Capital Management, Nebula Research & Development, and HUB Investment Partners.
The article details recent insider selling activity where Vice Presidents M Kathryn Fink and Robert S. Fletcher sold a combined total of 9,764 shares under pre-arranged Rule 10b5-1 trading plans. Additionally, sixteen equity research analysts currently rate the stock as a 'Moderate Buy' with an average price target of $395.33, though recent downgrades from Wall Street Zen and Leerink Partners have tempered expectations.
Stryker Corporation reported a quarterly dividend of $0.88 per share payable on July 31st to stockholders of record as of June 30th, resulting in an annualized yield of 1.1%. The company maintains a market capitalization of $125.13 billion with a P/E ratio of 37.78 and a debt-to-equity ratio of 0.62, trading between a twelve-month low of $281.00 and a high of $404.87.
📉 AdvisorShares reduced Stryker stake by 8.8% to $6.12 million.
📈 Marshall Wace surged position by 107.9% in Q2.
💰 New buyers acquired combined stakes of $677,000.
💸 Insiders sold 323,264 shares worth $100.66 million.
📊 Analysts rate stock 'Moderate Buy' with $395.33 target.
📉 AdvisorShares Investments LLC reduced its Stryker position by 8.8% in Q1, selling 1,794 shares to retain a $6.12 million stake.
📈 Brighton Jones LLC increased its holding by 15.4%, while Marshall Wace LLP surged its position by 107.9% in the second quarter.
💰 New institutional buyers Schnieders Capital, Nebula Research, and HUB Investment Partners acquired stakes valued at approximately $677,000 combined.
📉 Vice Presidents M Kathryn Fink and Robert S. Fletcher sold 5,220 and 4,544 shares respectively under Rule 10b5-1 trading plans.
💸 Total insider selling reached 323,264 shares valued at $100.66 million over the last 90 days.
📊 Analyst consensus remains 'Moderate Buy' with an average price target of $395.33 despite recent downgrades from Wall Street Zen and Leerink Partners.
💵 Stryker declared a quarterly dividend of $0.88 per share, offering a 1.1% annualized yield to shareholders of record by June 30th.
📈 Financial metrics show a market cap of $125.13 billion, a P/E ratio of 37.78, and a healthy debt-to-equity ratio of 0.62.
📉 Stock price fluctuates between a twelve-month low of $281.00 and a high of $404.87 with a current fifty-day moving average of $309.80.
Bullish Signals
Marshall Wace increased position by 107.9% to 77,831 shares.
Brighton Jones boosted stake by 15.4% adding 609 shares.
Three new investors initiated positions totaling $677,000.
Strong balance sheet: Quick ratio 1.25, Current ratio 2.11.
Analysts rate Moderate Buy with $395.33 price target.
Risk Factors
AdvisorShares Investments LLC cut position by 8.8% in Q1.
Analyst downgrades from Wall Street Zen and Leerink Partners.
Insiders sold 323,264 shares worth $100.66 million recently.
Vice Presidents reduced holdings by 28.44% and 30.04%.
Bullish Signals
Marshall Wace LLP significantly increased its position by 107.9% in the second quarter, acquiring an additional 77,831 shares.
Brighton Jones LLC boosted its stake by 15.4%, adding 609 shares to its existing portfolio.
Three new institutional investors—Schnieders Capital Management, Nebula Research & Development, and HUB Investment Partners—initiated new positions totaling approximately $677,000.
The company maintains a strong balance sheet with a quick ratio of 1.25, current ratio of 2.11, and a low debt-to-equity ratio of 0.62.
Analysts maintain a 'Moderate Buy' consensus rating with an average price target of $395.33, indicating continued institutional interest.
Risk Factors
AdvisorShares Investments LLC reduced its position by 8.8% during the first quarter, signaling some institutional caution.
Recent analyst downgrades from Wall Street Zen and Leerink Partners suggest potential short-term pressure on the stock price.
Significant insider selling activity occurred in the last 90 days, with insiders offloading 323,264 shares valued at $100.66 million.
Vice Presidents M Kathryn Fink and Robert S. Fletcher reduced their personal holdings by 28.44% and 30.04% respectively.
Stryker Corporation (SYK) is a global medical technology leader specializing in orthopedic implants, surgical equipment, and hospital infrastructure products. The company's portfolio includes hip and knee replacement systems, trauma devices, spine products, endoscopic tools, and patient transport equipment. Stryker also plays a significant role in robot-assisted orthopedic surgery through its Mako platform, which supports procedures like knee and hip replacements.
The company operates in markets driven by aging demographics, increasing procedure volumes, hospital investment cycles, and demand for technologies that improve surgical precision and patient recovery. In reconstructive orthopedics, Stryker competes with a small number of major global manufacturers, while holding a particularly strong position in operating room equipment such as surgical lights, ceiling boom systems, and communication systems.
From an investor perspective, Stryker is viewed as a large-scale healthcare equipment company with a diversified product base, strong relationships with surgeons, and exposure to long-term growth in musculoskeletal care, minimally invasive procedures, and hospital modernization. The business model combines durable implant franchises with recurring demand for disposables, instruments, and renewal equipment.
Recent technical analysis indicates that while the stock price is above its 50-day moving average, the 200-day moving average still points lower. Analyst sentiment remains strongly positive, with 82% of analysts rating Stryker as a Buy. However, insider selling has been a notable factor, with insiders net selling approximately $37.5 million in stock over the last 90 days.
🏥 Global leader in orthopedic implants and hospital infrastructure.
🤖 Key player in robot-assisted surgery via Mako platform.
📈 Strong analyst sentiment with 82% rating as Buy.
📉 Significant insider selling of $37.5M over last 90 days.
🔍 Technical indicators show bullish momentum and RSI strength.
🏥 Stryker Corporation is a global leader in orthopedic implants, surgical equipment, and hospital infrastructure products.
🤖 The company is a key player in robot-assisted orthopedic surgery via its Mako platform for knee and hip replacements.
📈 Analyst sentiment is strongly positive with 82% of analysts rating Stryker as a Buy.
📉 Insider selling has been significant, with net sales of approximately $37.5 million over the last 90 days.
📊 Technical indicators show the stock price above the 50-day moving average but below the 200-day moving average.
🔍 MACD momentum is supportive and RSI is bullish, suggesting near-term technical strength.
🌍 Stryker generates significant revenue from international health systems beyond its primary US market.
💼 The company benefits from durable implant franchises and recurring demand for surgical disposables.
📉 No meaningful insider purchases were recorded during the recent 90-day period.
Bullish Signals
82% of analysts rate Stryker as a Buy.
MACD momentum and RSI show bullish trends.
Stock trades above its 50-day moving average.
Diversified product base includes durable implant franchises.
Exposure to aging demographics and hospital modernization.
Risk Factors
Insiders sold $37.5M in stock over last 90 days.
No meaningful insider purchases recorded recently.
200-day moving average still points lower than price.
Bullish Signals
Analyst sentiment remains strongly positive with 82% of analysts rating Stryker as a Buy, indicating strong institutional confidence in the company's prospects.
Technical signals are supportive in the near term, with MACD momentum being supportive and RSI showing bullish trends.
The stock price is trading above its 50-day moving average, suggesting short-term upward momentum despite the lower 200-day average.
Stryker benefits from a diversified product base including durable implant franchises and recurring demand for surgical disposables and instruments.
The company has strong relationships with surgeons and exposure to long-term growth drivers like aging demographics and hospital modernization.
Risk Factors
Insiders were net sellers of approximately $37.5 million in Stryker stock over the last 90 days, indicating a lack of insider buying interest.
No meaningful insider purchases were recorded during the recent period, which can be interpreted as a cautionary signal for investors.
The 200-day moving average still points lower than the current price, suggesting that long-term technical trends have not yet fully turned bullish.
Apollon Wealth Management LLC significantly reduced its stake in Stryker Corporation (NYSE:SYK) by 62.2% during the first quarter, selling 16,099 shares to retain a position of 9,787 shares valued at $3,216,000. In contrast, several other major institutional investors increased their holdings in the fourth quarter. Vanguard Group Inc. grew its stake by 0.4% to own 33,907,291 shares worth approximately $11.9 billion, while State Street Corp and Geode Capital Management LLC also lifted their positions by 2.1% and 0.9%, respectively. Wellington Management Group LLP saw the most aggressive growth among these investors, increasing its holdings by 22.6% to own 6,493,276 shares valued at $2.28 billion. Alliancebernstein L.P. also expanded its stake by 13.3% in the third quarter. Collectively, hedge funds and other institutional investors hold 77.09% of the company's stock.
Analyst sentiment regarding Stryker remains mixed with recent adjustments to price targets across major financial institutions. William Blair reissued an "outperform" rating on March 5th, while Barclays, Wells Fargo & Company, JPMorgan Chase & Co., and Needham & Company LLC all lowered their price targets in May, ranging from $394.00 to $418.00, though they maintained "overweight" or "buy" ratings. The consensus rating is currently a "Moderate Buy" with an average target price of $395.33 based on sixteen buy ratings and six hold ratings. Despite the positive institutional accumulation, insider activity has been notable; VP M Kathryn Fink sold 5,220 shares for $1.48 million in May, and Director Ronda E. Stryker sold 310,000 shares for $96.79 million on May 26th, representing a 13.87% decrease in her position.
Financially, Stryker reported quarterly earnings of $2.60 EPS in the quarter ended April 30th, missing analyst estimates of $2.98 by $0.38. The company generated revenue of $6.02 billion, a 2.6% increase year-over-year but below the expected $6.34 billion. Key financial metrics include a market capitalization of $120.69 billion, a price-to-earnings ratio of 36.44, and a beta of 0.78. The stock recently opened at $314.81, trading between a 52-week low of $281.00 and a high of $404.87. Additionally, the company declared a quarterly dividend of $0.88 per share payable on July 31st to shareholders of record as of June 30th, resulting in an annualized yield of 1.1%. Stryker has set its fiscal year 2026 guidance between 14.900 and 15.100 EPS, while analysts forecast a full-year EPS of 14.98.
📉 Apollon Wealth trimmed Stryker holdings by 62.2% to 9,787 shares.
📈 Wellington Management increased stake by 22.6%, adding $2.28 billion.
📉 Analysts lowered price targets ranging from $394 to $418.
📉 Q1 EPS missed estimates at $2.60 vs expected $2.98.
Stryker Corporation (NYSE: SYK) recently experienced a share price pullback of 5.1% year-to-date and 15.6% over the past year, despite an 8.5% gain in the last week. The stock currently trades at $330.52 per share, presenting a mixed valuation picture depending on the analytical framework used.
A Discounted Cash Flow (DCF) analysis projects Stryker's intrinsic value at $379.17 per share based on free cash flow estimates extending to 2035. This model suggests the stock is undervalued by approximately 12.8%, as the current price is below the calculated fair value derived from future cash projections.
However, traditional valuation metrics indicate a premium multiple. Stryker trades at a Price-to-Earnings (P/E) ratio of 37.97x, which is significantly higher than the Medical Equipment industry average of 25.90x and the peer group average of 28.45x. The company's proprietary 'Fair Ratio' model suggests a suitable P/E of 31.39x, implying the stock may be overvalued relative to its earnings growth expectations.
The article concludes by highlighting Simply Wall St's 'Narratives' tool, which allows investors to build custom financial models with varying assumptions for revenue and margins. This approach can reconcile the divergence between the optimistic DCF valuation and the conservative P/E multiple, offering a range of potential fair values from $315 to $465.
📊 DCF analysis implies intrinsic value of $379.17 per share.
📈 Trades at 37.97x P/E, higher than industry average of 25.90x.
🎯 Fair Ratio model suggests suitable P/E of 31.39x.
📉 Stryker stock is down 15.6% over the past year but has rebounded with an 8.5% gain in the last week.
💰 The company generated approximately $4.6 billion in free cash flow over the latest twelve months.
📊 DCF analysis estimates an intrinsic value of $379.17 per share, implying a 12.8% discount to current price.
📈 Stryker trades at a P/E ratio of 37.97x, which is higher than the industry average of 25.90x.
🎯 The proprietary Fair Ratio model suggests a suitable P/E of 31.39x, indicating potential overvaluation on earnings multiples.
🧠 Investors can use Simply Wall St's 'Narratives' tool to customize revenue and margin assumptions for fair value estimation.
📅 Analysts provide explicit free cash flow estimates extending through the year 2028.
Bullish Signals
DCF model shows 12.8% undervaluation with $379.17 intrinsic value.
Risk Factors
P/E ratio of 37.97x exceeds industry average of 25.90x.
Valuation significantly higher than peer average of 28.45x.
Fair Ratio model suggests suitable P/E of 31.39x.
Bullish Signals
DCF model indicates Stryker is undervalued by 12.8% with an intrinsic value of $379.17 compared to the current price of $330.52.
The company has demonstrated long-term growth, showing gains over both 3 and 5 year periods despite recent annual declines.
Analysts provide explicit free cash flow projections extending out to 2028, indicating a stable outlook for future earnings generation.
Risk Factors
Stryker trades at a P/E ratio of 37.97x, which is significantly higher than the Medical Equipment industry average of 25.90x and peer average of 28.45x.
The proprietary Fair Ratio model suggests a suitable P/E of 31.39x, implying the stock may be pricing in excessive optimism relative to its risk profile.
Stryker Corp. (SYK) shares rallied 5.25% to close at $332.71 on Friday, marking a strong performance despite a broader market decline where the S&P 500 fell 0.05% and the Dow Jones Industrial Average dropped 0.09%. This positive move occurred in an environment characterized by an all-around rough trading session for the general stock market.
The rally represents the fourth consecutive day of gains for Stryker Corp., highlighting a sustained period of outperformance relative to its competitors and the wider index. While the article does not detail specific earnings or operational drivers, the consistent upward momentum suggests strong investor confidence in the company's immediate trajectory.
📈 SYK shares rallied 5.25% to $332.71 on Friday.
🚀 Stock posted fourth consecutive day of gains.
📉 Rally occurred while S&P 500 and Dow fell.
🏆 Company outperformed competitors during market decline.
📈 Stryker Corp. (SYK) shares rallied 5.25% to $332.71 on Friday.
🚀 This was the fourth consecutive day of gains for the stock.
📉 The rally occurred while the broader market declined, with the S&P 500 falling 0.05% and the Dow Jones dropping 0.09%.
🏆 Stryker Corp. outperformed competitors during this rough trading session.
Bullish Signals
Shares gained 5.25% to close at $332.71.
Stock posted gains for four consecutive days.
Bullish Signals
SYK shares gained 5.25% to close at $332.71, demonstrating significant strength relative to the broader market decline.
The stock has posted gains for four consecutive days, indicating sustained positive momentum and investor interest.
Stryker (SYK) has received positive attention following a federal court ruling in its favor regarding an OptaBlate patent dispute. This legal victory alleviates concerns over the company's intellectual property as it simultaneously advances new surgical products and increases adoption of its Mako robotics platform.
Despite these developments, Stryker's short-term share price momentum has weakened, with the stock down 12.49% year-to-date and an 18.87% decline in total shareholder return over the past year. However, longer-term returns remain resilient, showing a 5.67% gain over three years and a 23.23% gain over five years.
Analysts suggest Stryker could be undervalued by approximately 21.2%, with a calculated fair value of $386.80 compared to the recent closing price of $304.69. The company's robust innovation pipeline in robotic-assisted surgery is expected to drive market share growth, higher average selling prices, and margin expansion over time.
Valuation metrics present mixed signals; while cash flow models indicate undervaluation, Stryker trades at a 35x P/E ratio, which is significantly higher than the peer average of 28x. Investors must weigh the potential for future growth against risks such as regulatory delays and margin pressures from inflation or tariffs.
Stryker Corporation (SYK) is a global medical technology leader with a market cap of $118.4 billion, operating in Orthopaedics, MedSurg, and Neurotechnology. Despite facing an unexpected cyber disruption that impacted first-quarter results, the company maintains strong underlying demand, a robust capital order book, and significant international momentum. Management emphasizes that organic sales growth was constrained by shipment delays rather than weakening customer demand.
The article highlights Stryker's strategic advantages in its robotics ecosystem, particularly the Mako platform, which saw record installations and increasing utilization rates globally. The company is expanding this ecosystem with new handheld solutions and advanced hip revision procedures to strengthen its competitive moat. International markets, including Japan, Europe, India, and the Middle East, are emerging as major growth engines with significant room for market share expansion.
However, Stryker faces several headwinds including margin pressures from tariffs, inflation, and lost manufacturing absorption following the cyberattack. The company also takes on execution risks by expanding into newer categories like cardiovascular technologies and AI-enabled solutions, which adds operational complexity. Analysts note a positive estimate revision trend for 2026, with earnings expected to improve 10.6% over the next five years.
Zacks Investment Research maintains a 'Hold' rating (Rank #3) on SYK, noting its shares have underperformed the industry and S&P 500 year-to-date despite solid fundamentals. The consensus estimate for second-quarter 2026 revenues is pegged at $6.56 billion, implying an 11.5% bottom-line growth. While the cyberattack exposes operational vulnerabilities, management has successfully restored systems and reaffirmed full-year guidance.
📈 SYK shares down 13.1% YTD vs industry's 23.1% decline.
💻 Cyberattack caused 190 basis point adjusted gross margin drop.
🤖 Mako robotics platform achieved record global installations and growth.
🌍 International markets in Japan, Europe, India drive major expansion.
⚠️ Tariffs and input costs threaten future margin improvement goals.
📈 Stryker (SYK) holds a Zacks Rank #3 (Hold) with shares down 13.1% YTD versus the industry's 23.1% decline.
💻 A recent cyberattack disrupted Q1 manufacturing and revenue recognition, causing adjusted gross margin to decline 190 basis points.
🤖 The Mako robotics platform achieved record installations globally with increasing utilization rates and new handheld solutions launching.
🌍 International operations are becoming a major growth engine with strong momentum in Japan, Europe, India, and the Middle East.
💰 Management expects SYK's bottom line to improve 10.6% over the next five years despite current margin pressures.
📉 Q2 2026 revenue consensus is pegged at $6.56 billion, implying an 11.5% year-over-year growth in earnings.
⚠️ Margin expansion faces headwinds from tariffs, rising input costs, freight expenses, and geopolitical developments.
🔬 Expansion into peripheral vascular intervention and AI-enabled hospital solutions adds execution complexity and regulatory uncertainty.
🛡️ Management successfully restored manufacturing systems after the cyberattack but warns of future cybersecurity threats.
📊 The company has a market capitalization of $118.4 billion and operates across Orthopaedics, MedSurg, and Neurotechnology.
Bullish Signals
Healthy demand and elevated order book ensure future revenue visibility.
Record Mako installations prove a strong competitive moat in robotics.
International expansion opportunities exist in Japan, Europe, India, and Middle East.
SYK beat earnings estimates for four quarters with minimal surprise.
New Mako RPS product broadens surgical access globally.
Worldwide Healthcare Trust PLC reported that AstraZeneca PLC was its top contributor to portfolio performance for the financial year ended March 31, with net asset value per share reaching 371.0 pence, a 9.3% increase from the prior year's 339.5 pence. The trust achieved a NAV total return of 10.0%, significantly outperforming its MSCI World Health Care index benchmark which returned just 1.8%. AstraZeneca was highlighted as the premier global diversified pharmaceutical player with leading franchises in oncology, respiratory, rare disease, and cardiovascular disease, supported by a portfolio of 16 distinct blockbuster medicines and numerous phase 3 clinical trials.
Conversely, surgical equipment firm Stryker Corp served as the top detractor due to macro rotation out of MedTech stocks and investor skepticism regarding volume growth, despite a fourth quarter net sales increase of 11.4%. Other notable contributors included GC Oncology, Exact Sciences, Avidity Biosciences, and Apellis Pharmaceutical, while Vertex Pharmaceuticals, Daiichi Sankyo, UnitedHealth Group, and Boston Scientific were among the top detractors. The trust's chair, Doug McCutcheon, noted that merger and acquisition activity was a meaningful contributor to performance and expressed a positive long-term outlook for global equities and the healthcare sector, citing supportive US regulatory environments and attractive valuations in biotechnology.
📈 NAV rose 9.3% to 371.0 pence, outperforming the benchmark by 8.2%.
💊 AstraZeneca led gains while Stryker dragged performance down due to rotation.
🔄 Doug McCutcheon retires as Chair; William Hemmings will succeed him.
📈 Worldwide Healthcare Trust reported a net asset value per share of 371.0 pence as of March 31, representing a 9.3% increase from the previous year.
📊 The fund achieved a NAV total return of 10.0% for the financial year ended March 31, significantly outperforming its MSCI World Health Care index benchmark which returned just 1.8%.
💊 AstraZeneca PLC was identified as the top contributor to portfolio performance, with the London-based pharma giant being the only Europe-based company in the fund's top five contributors.
🔬 Management praised AstraZeneca for solidifying its status as a premier global player with leading franchises in oncology, respiratory, rare disease, and cardiovascular disease.
⚠️ Stryker Corp was the top detractor from performance, pressured by a macro rotation out of MedTech stocks and investor skepticism regarding volume growth despite an 11.4% net sales increase in Q4.
🔍 Other notable detractors included Vertex Pharmaceuticals Inc, Tokyo-based Daiichi Sankyo Co Ltd, UnitedHealth Group Inc, and Boston Scientific Corp.
🤝 Merger and acquisition activity was cited as a meaningful contributor to the fund's overall performance during the reported period.
🌐 The firm noted that US healthcare policy uncertainty lifted late in 2025, leading biotechnology and pharmaceutical sub-sectors to begin outperforming.
👴 Doug McCutcheon, the current Chair of Worldwide Healthcare, announced he will retire after the company's annual general meeting on July 14.
🔄 William Hemmings is set to succeed Doug McCutcheon as the new Chair following his retirement at the upcoming AGM.
📉 Shares in Worldwide Healthcare were trading 0.3% higher at 346.88 pence each on Friday morning in London.
🌍 The portfolio manager and board remain positive on the long-term outlook for global equities, particularly within the global healthcare sector.
💰 Large cap pharmaceutical companies are facing patent expiry pressures, prompting heavy investment in innovative pipelines and continued M&A activity in biotechnology.
📉 The fund's benchmark is the MSCI World Health Care index on a net total return sterling adjusted basis.
🏥 The top five contributors included GC Oncology, Exact Sciences, Avidity Biosciences, and Apellis Pharmaceutical alongside AstraZeneca.
Bullish Signals
NAV per share rose 9.3% to 371.0 pence.
Fund NAV return of 10.0% beat benchmark by 8.2%.
AstraZeneca led performance with strong oncology and respiratory franchises.
Portfolio includes 16 blockbuster medicines and active phase 3 trials.
M&A activity significantly boosted overall fund performance.
MedTech sector vulnerable to rotation and Boston Scientific sentiment shifts.
Large cap pharma pressured by patent expiries forcing pipeline investment.
Bullish Signals
Worldwide Healthcare Trust's net asset value per share reached 371.0 pence as of March 31, representing a strong 9.3% increase from the previous year.
The fund delivered a NAV total return of 10.0% for the financial year ended March 31, significantly outperforming its benchmark MSCI World Health Care index which returned only 1.8%.
AstraZeneca was identified as the top contributor to portfolio performance, solidifying its status with leading franchises in oncology, respiratory, rare disease, and cardiovascular disease.
The company highlighted an impressive breadth of innovation including a plethora of announced phase 3 clinical trials and a portfolio of 16 distinct blockbuster medicines.
Merger & acquisition activity was noted as a meaningful contributor to the fund's overall performance.
US healthcare policy uncertainty lifted late in 2025, leading biotechnology and pharmaceutical sub-sectors to begin outperforming.
The board remains positive on the long-run outlook for global equities and specifically for the global healthcare sector.
Large cap pharmaceutical companies are investing heavily in innovative pipelines due to patent expiry pressures, creating a strong incentive for continued M&A activity in the biotechnology sector where valuations remain attractive.
Risk Factors
Stryker Corp was identified as the top detractor in the portfolio due to investor skepticism regarding volume growth, despite a reported fourth quarter net sales increase of 11.4%.
The stock pressure on Stryker was exacerbated by macro rotation out of MedTech stocks and the 'Boston Scientific Effect', highlighting the sector's vulnerability to sudden shifts in investor sentiment regarding hospital capital expenditures.
Doug McCutcheon noted that large cap pharmaceutical companies continue to face significant patent expiry pressures, which forces them to invest heavily in innovative pipelines.
Stryker Corp (NYSE: SYK) director Ronda E Stryker executed a significant insider sell on May 28, disposing of 310,000 shares valued at $96.79 million according to an SEC Form 4 filing submitted Thursday. This transaction represents a substantial reduction in equity but is one of many factors investors must consider alongside the broader financial landscape surrounding the medical device leader.
The article provides detailed context on Stryker's current financial metrics, noting a revenue growth rate of approximately 2.63% for the period ending March 31, 2026, though this trails its industry peers in the Health Care sector. The company maintains a debt-to-equity ratio of 0.64, which is higher than the industry average, suggesting a greater reliance on borrowed funds compared to competitors. Conversely, Stryker boasts a robust market position with a gross margin of 63.29% and earnings per share significantly outperforming industry norms.
Valuation analysis indicates mixed signals regarding stock price relative to fundamentals; the company trades at a P/E ratio of 35.61, which is below industry norms suggesting potential undervaluation, yet its Price-to-Sales ratio of 4.71 and high EV/EBITDA of 20.14 suggest elevated valuations based on sales and enterprise value metrics. Roughly one-fourth of Stryker's revenue currently originates from international markets outside the United States, highlighting its global exposure in reconstructive orthopedic implants and operating room equipment where it holds a leadership position.
📉 Director Ronda E Stryker sold $96.8M worth of shares on May 28.
📈 Stock rose 0.34% to $308.67 with 2.63% revenue growth in Q1 2026.
⚠️ Revenue lags peers while debt-to-equity (0.64) exceeds industry averages.
💰 High gross margin of 63.29% and EPS of $1.95 outperform competitors.
🌍 One-fourth of revenue comes from international markets outside the US.
📉 Director Ronda E Stryker sold 310,000 shares of Stryker (NYSE: SYK) on May 28, according to an SEC Form 4 filing.
💰 The total value of the insider sale was $96,792,668 at the time of execution.
📈 Stryker's stock is trading at $308.67 and rose 0.34% during Friday's morning session.
📊 Over a three-month period ending March 31, 2026, the company reported revenue growth of approximately 2.63%.
⚠️ This revenue growth rate trails behind the average among peers in the Health Care sector.
💳 Stryker's debt-to-equity ratio stands at 0.64, which is notably higher than the industry average.
🏢 The company maintains a market capitalization that surpasses industry standards, indicating a robust market position.
📝 Insider transactions are legally required to be disclosed via Form 4 filings within two business days of the trade.
🤔 Insider sales do not necessarily signal a bearish stance and can be motivated by various personal or financial factors.
🦴 Stryker designs and markets medical equipment including hip and knee replacements, orthopedic robotics, and operating room equipment.
🌍 Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
💵 The company boasts a high gross margin of 63.29%, reflecting superior cost management compared to peers.
📉 Current earnings per share (EPS) is $1.95, which is significantly higher than the industry average.
📈 The current P/E ratio of 35.61 is below industry norms, suggesting potential undervaluation.
📉 Conversely, the P/S ratio of 4.71 is above industry norms, reflecting an elevated valuation based on sales performance.
🔢 A high EV/EBITDA ratio of 20.14 positions the company as more valued compared to industry benchmarks.
📊 Transaction codes in Form 4 filings use 'S' for sales, 'P' for purchases, and 'C' for option conversions.
🏛️ Under Section 12 of the Securities Exchange Act of 1934, insiders include officers, directors, or beneficial owners holding more than ten percent of equity.
Bullish Signals
Stryker shares gained 0.34% at $308.67.
Revenue grew 2.63% by March 2026.
Gross margin stands high at 63.29%.
EPS of $1.95 exceeds industry average.
P/E ratio of 35.61 suggests undervaluation.
Leader in orthopedic implants and OR equipment.
International revenue comprises roughly one-fourth.
Risk Factors
Director sold $96.79M shares, signaling potential stock concerns.
Revenue growth of 2.63% trails Health Care sector peers.
Debt-to-equity ratio of 0.64 exceeds industry averages.
P/S ratio of 4.71 indicates elevated valuation risk.
EV/EBITDA of 20.14 suggests potential overvaluation.
Bullish Signals
Stryker's shares are actively trading at $308.67, experiencing a gain of 0.34% during Friday's morning session.
The company achieved a revenue growth rate of approximately 2.63% as of March 31, 2026, indicating a substantial increase in top-line earnings.
Stryker maintains a high gross margin of 63.29%, reflecting superior cost management and profitability compared to its peers.
The company demonstrates robust bottom-line performance with a current EPS of $1.95, which is significantly higher than the industry average.
With a P/E ratio of 35.61, Stryker's valuation is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment.
Roughly one-fourth of Stryker's total revenue currently comes from outside the United States, demonstrating strong international market presence.
Risk Factors
Director Ronda E Stryker executed a substantial insider sell of $96.79M worth of shares on May 28, which may signal concerns about future stock performance despite management's stated neutrality.
Stryker's revenue growth rate of approximately 2.63% trails behind the average among peers in the Health Care sector, indicating slower top-line expansion relative to competitors.
The company's debt-to-equity ratio stands at 0.64, which is notably higher than the industry average and raises concerns about financial leverage and reliance on borrowed funds.
Stryker's current P/S ratio of 4.71 is above industry norms, reflecting an elevated valuation that could present downside risk if sales growth does not accelerate to justify the premium.
The company's EV/EBITDA ratio of 20.14 positions it as more valued compared to industry benchmarks, suggesting potential overvaluation relative to earnings power.
Your Privacy
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Measure audience engagement and site statistics to understand how our services are used (Google Analytics)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
You can accept all cookies or configure your preferences. You can change them at any time via the "Manage Cookies" link in the footer.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Analytics cookies
Help us understand how visitors interact with our website using Google Analytics. These cookies collect information anonymously.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
